Pressmeddelande —
Direct renin inhibitor Aliskiren as effective as Losartan
Results of the ALLAY* study, published in Circulation, shows that Aliskiren is as effective as Losartan in reducing LV mass.
The follow-up (after 36 weeks) also showed that Aliskiren proved equally effective in lowering blood pressure. The study population, consisting of overweight hypertensive patients with LV hypertrophy**, was evaluated using the latest technology (MRI and ECG). Aliskiren is the first orally active direct renin inhibitor.
All study ECG´s have been evaluated by A+ Science in cooperation with Sahlgrenska University Hospital/Östra. Medical Advisor Dr Björn Dahlöf has contributed to planning and study design.
*Aliskiren in Left Ventricular Hypertrophy (ALLAY)
Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy (Solomon SD et al Circulation 2009;119:530-537).
**Left ventricular hypertrophy (LVH) is the thickening of the myocardium (muscle) of the left ventricle of the heart (Wikipedia).
Ämnen
- Hälsa, sjukvård, läkemedel
Kategorier
- allay study
- aliskiren
- lowering blood pressure
- direct renin inhibitor
- ecg
- orally active
- nordic cro
- clinical trial
- scandinavia
- contract research organisation
- clinical research
A+ Science is a Nordic Contract Research Organisation, planning and conducting clinical trials on behalf of drug and medical device developers from all over the world. We help our customers bring their products to market faster.
In addition to traditional CRO services, we offer controlled patient recruitment, mobile research units and outsourcing of research staff directly to site.
